Topics

Glioblastoma | Treatment | Clinical trials | CAR-T-Cells

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > CAR-T-Cells

Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM.
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Nat Cancer. 2024 Jan 12. doi: 10.1038/s43018-023-00709-6. PMID: 38216766. Interventional study˰ ˍ

Begley SL, O'Rourke DM, Binder ZA.
CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials.
Mol Ther. 2025 Mar 7:S1525-0016(25)00178-9. doi: 10.1016/j.ymthe.2025.03.004. PMID: 40057825. Review. ˍ

**Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q.
Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas.
J Transl Med. 2025 May 27;23(1):591. doi: 10.1186/s12967-025-06523-1. PMID: 40420236. Interventional study. ˍ

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM.
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2025 Jun 1. doi: 10.1038/s41591-025-03745-0. PMID: 40451950. Interventional study. ˍ

Chan JTN, Henley-Waters J, Kayhanian S.
Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review.
Neurooncol Adv. 2025 Jun 3;7(1):vdaf115. doi: 10.1093/noajnl/vdaf115. PMID: 40626039. Review. ˍ AI Overview

Barish ME, Aftabizadeh M, Hibbard J, Blanchard MS, Ostberg JR, Wagner JR, Manchanda M, Paul J, Stiller T, Aguilar B, Starr R, Arvanitis L, Ressler JA, Kilpatrick J, Kong Y, Wang D, Forman SJ, D'Apuzzo M, Brown CE, Badie B.
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety.
Cell Rep Med. 2025 Aug 15;6(8):102302. doi: 10.1016/j.xcrm.2025.102302. PMID: 40818458. Interventional study. ˍ ClinicalTrrials.gov ID: NCT04214392.